These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 29685206)

  • 61. Is multiple sclerosis caused by an oral spirochaete?
    Gay D; Dick G
    Lancet; 1986 Jul; 2(8498):75-7. PubMed ID: 2873382
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Nonlinear dynamics and multiple sclerosis.
    Bharanidharan P
    J Neurol Sci; 1997 Aug; 149(2):139-40. PubMed ID: 9171320
    [No Abstract]   [Full Text] [Related]  

  • 63. Transition to space-time chaos in a nonlinear optical system with two-dimensional feedback.
    Ramazza PL; Residori S; Pamapaloni E; Larichev AV
    Phys Rev A; 1996 Jan; 53(1):400-407. PubMed ID: 9912896
    [No Abstract]   [Full Text] [Related]  

  • 64. Erratum: Transition to space-time chaos in a nonlinear optical system with two-dimensional feedback.
    Ramazza PL; Residori S; Pamapaloni E; Larichev A
    Phys Rev A; 1996 Jul; 54(1):982. PubMed ID: 9913564
    [No Abstract]   [Full Text] [Related]  

  • 65. Chaos theory.
    Kyriazis M
    BMJ; 1992 Jan; 304(6820):186. PubMed ID: 1737174
    [No Abstract]   [Full Text] [Related]  

  • 66. Chaos, but in voting and apportionments?
    Saari DG
    Proc Natl Acad Sci U S A; 1999 Sep; 96(19):10568-71. PubMed ID: 10485863
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Controlling chaos in high dimensions: Theory and experiment.
    Ding M; Yang W; In V; Ditto WL; Spano ML; Gluckman B
    Phys Rev E Stat Phys Plasmas Fluids Relat Interdiscip Topics; 1996 May; 53(5):4334-4344. PubMed ID: 9964766
    [No Abstract]   [Full Text] [Related]  

  • 68. 'No evidence of disease activity' - is it an appropriate surrogate in multiple sclerosis?
    Hegen H; Bsteh G; Berger T
    Eur J Neurol; 2018 Sep; 25(9):1107-e101. PubMed ID: 29687559
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Rebound disease in multiple sclerosis.
    Giacomini PS
    Mult Scler; 2018 Jul; 24(8):1137-1138. PubMed ID: 29708464
    [No Abstract]   [Full Text] [Related]  

  • 70. Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: The MIRROR study.
    Bar-Or A; Grove RA; Austin DJ; Tolson JM; VanMeter SA; Lewis EW; Derosier FJ; Lopez MC; Kavanagh ST; Miller AE; Sorensen PS
    Neurology; 2018 May; 90(20):e1805-e1814. PubMed ID: 29695594
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Comprehensive systematic review summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.
    Rae-Grant A; Day GS; Marrie RA; Rabinstein A; Cree BAC; Gronseth GS; Haboubi M; Halper J; Hosey JP; Jones DE; Lisak R; Pelletier D; Potrebic S; Sitcov C; Sommers R; Stachowiak J; Getchius TSD; Merillat SA; Pringsheim T
    Neurology; 2018 Apr; 90(17):789-800. PubMed ID: 29686117
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Complexity of MS management in the current treatment era.
    Chitnis T; Giovannoni G; Trojano M
    Neurology; 2018 Apr; 90(17):761-762. PubMed ID: 29686111
    [No Abstract]   [Full Text] [Related]  

  • 73. Peripheral blood monocyte count at onset may affect the prognosis in multiple sclerosis.
    Akaishi T; Takahashi T; Nakashima I
    J Neuroimmunol; 2018 Jun; 319():37-40. PubMed ID: 29685288
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Morphometric analysis of axons in the minute multiple sclerosis lesions and shadow plaques in patients with multiple sclerosis.
    Nowacki P; Potemkowski A; Korwin-Piotrowska T; Nocoń D
    Folia Neuropathol; 2000; 38(3):104-10. PubMed ID: 11043971
    [TBL] [Abstract][Full Text] [Related]  

  • 75. [Clinical subtypes of multiple sclerosis and the immuno-pathogeneses].
    Fujihara K
    Nihon Rinsho; 2003 Aug; 61(8):1293-9. PubMed ID: 12962014
    [TBL] [Abstract][Full Text] [Related]  

  • 76. MRI phenotypes based on cerebral lesions and atrophy in patients with multiple sclerosis.
    Tauhid S; Neema M; Healy BC; Weiner HL; Bakshi R
    J Neurol Sci; 2014 Nov; 346(1-2):250-4. PubMed ID: 25220114
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Chaos theory for clinical manifestations in multiple sclerosis.
    Akaishi T; Takahashi T; Nakashima I
    Med Hypotheses; 2018 Jun; 115():87-93. PubMed ID: 29685206
    [TBL] [Abstract][Full Text] [Related]  

  • 78. A minimal unified model of disease trajectories captures hallmarks of multiple sclerosis.
    Kannan V; Kiani NA; Piehl F; Tegner J
    Math Biosci; 2017 Jul; 289():1-8. PubMed ID: 28365299
    [TBL] [Abstract][Full Text] [Related]  

  • 79.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 80.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.